Cardio Diagnostics Holdings Inc.
CDIO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CDIO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CDIO
Cardio Diagnostics Holdings Inc. is an early-stage precision cardiovascular diagnostics company that develops AI-driven epigenetic tests for heart disease, stroke, and diabetes, with no current revenue and a history of operating losses.
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Cardio Diagnostics Holdings Inc. is an early-stage precision cardiovascular diagnostics company that develops AI-driven epigenetic tests for heart disease, stroke, and diabetes, with no current revenue and a history of operating losses.
- Cash and equivalents of $5.6M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net loss of -$1.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $7.0M as of 2026-06-30 [sec].
- Product pipeline includes tests for congestive heart failure, stroke, and diabetes [sec_mda · as of 2026-03-13].
- Company has incurred losses and negative cash flows from operations since inception and expects this to continue [sec_mda · as of 2026-08-07].
What works
- The company's AI-driven Multi-Omics Engine platform is built on over a decade of data and expert knowledge, enabling rapid development of new diagnostic solutions [sec_mda · as of 2026-03-13].
- Broad intellectual property portfolio includes seven patent families with issued patents in the U.S. and multiple international jurisdictions [sec_mda · as of 2026-03-13].
- Multiple product offerings for cardiovascular disease and other indications provide potential value propositions for healthcare stakeholders [sec_mda · as of 2026-03-13].
What to weigh
- The company has generated no revenue and has a history of operating losses and negative cash flows, with no expectation of near-term profitability [sec_mda · as of 2026-08-07].
- Clinical adoption of novel diagnostic technologies is lengthy and may take a decade or more, posing a barrier to revenue generation [sec_mda · as of 2026-05-15].
- The company expects to need additional capital and may face dilution from equity or convertible debt financing [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Ongoing need for additional financing
“We have had, and expect that we will continue to have, an ongoing need to raise additional cash from outside sources to fund our operations and grow our business”
SEC MD&A · May 15, 2026
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Company has zero revenue and sustained net losses, with negative cash flows from operations since inception [sec_mda · as of 2026-08-07].
- Need for additional capital — Company expects to need further financing through equity or debt, which may cause dilution [sec_mda · as of 2026-08-07].
- Slow clinical adoption — Broad clinical adoption of novel diagnostics can take multiple years to a decade or more [sec_mda · as of 2026-05-15].
- Regulatory uncertainty — Company is still evaluating FDA feedback and developing its regulatory strategy [sec_mda · as of 2026-03-13].
What to watch
- Progress of FDA regulatory strategy and any submissions [sec_mda · as of 2026-03-13].
- Market adoption of existing products and any new product launches [sec_mda · as of 2026-08-07].
- Ability to raise additional capital and terms of financing [sec_mda · as of 2026-05-15].
- Expansion into international markets, such as India [sec_mda · as of 2026-08-07].
Sources: News · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Cardio Diagnostics Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cardio Diagnostics Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
12.9 months
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$406K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 81,283 | $159K |
| vanguard capital management llc | 40,310 | $79K |
| blackrock, inc. | 34,708 | $68K |
| geode capital management, llc | 32,177 | $63K |
| renaissance technologies llc | 15,348 | $30K |
| vanguard fiduciary trust co | 3,969 | $8K |
| wolverine asset management llc | 104 | $203 |
| morgan stanley | 100 | $195 |
| hrt financial lp | 62,482 | $121 |
| osaic holdings, inc. | 16 | $31 |
Showing top 10 of 13 institutional holders of Cardio Diagnostics Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.6%
- Days to cover
- 0.7
- Shares short
- 46,815
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CDIO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cardio Diagnostics Holdings Inc.?
Cardio Diagnostics Holdings Inc. is an early-stage precision cardiovascular diagnostics company that develops AI-driven epigenetic tests for heart disease, stroke, and diabetes, with no current revenue and a history of operating losses.
Who is the CEO of Cardio Diagnostics Holdings Inc.?
Dr. Meeshanthini V. Dogan Ph.D. is the chief executive officer of Cardio Diagnostics Holdings Inc. (CDIO).
Where is Cardio Diagnostics Holdings Inc. headquartered?
Cardio Diagnostics Holdings Inc. (CDIO) is headquartered in Chicago, IL, United States.
What therapeutic areas does Cardio Diagnostics Holdings Inc. focus on?
Cardio Diagnostics Holdings Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.